Independent Research set a €103.00 ($119.77) price objective on Merck KGaA (FRA:MRK) in a research report report published on Thursday, September 19th, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
Other analysts also recently issued research reports about the company. DZ Bank reiterated a buy rating on shares of Merck KGaA in a research report on Wednesday, August 14th. JPMorgan Chase & Co. set a €100.00 ($116.28) price target on Merck KGaA and gave the company a neutral rating in a research report on Thursday, September 12th. Barclays set a €82.00 ($95.35) target price on Merck KGaA and gave the stock a sell rating in a research report on Wednesday, August 14th. Morgan Stanley set a €96.00 ($111.63) target price on Merck KGaA and gave the stock a neutral rating in a research report on Tuesday, September 10th. Finally, Credit Suisse Group set a €110.00 ($127.91) target price on Merck KGaA and gave the stock a buy rating in a research report on Friday, September 6th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of €101.33 ($117.83).
Shares of MRK traded up €0.05 ($0.06) during trading hours on Thursday, reaching €103.90 ($120.81). 479,151 shares of the company’s stock traded hands. The firm’s 50 day simple moving average is €99.51 and its 200-day simple moving average is €95.58. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Read More: Earnings Per Share
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.